Distinguishing Significant and Nonsignificant Risk Devices

Why is a SR or NSR Designation important?

The FDA guidance document, “Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors: Significant Risk and Nonsignificant Risk Medical Device Studies,” sheds some light on the Investigational Device Exemptions (IDE) regulations of 21 CFR 812. The IDE regulations describe significant risk (SR), nonsignificant risk (NSR), and exempt studies. For exempt studies, an institutional review board (IRB) does not determine whether the study is SR or NSR.  However, for all other studies, sponsors must make the initial risk determination of SR or NSR and present their proposed study to the IRB.  Thus, it is important that sponsors are able to distinguish significant and non-significant risk device studies. SR and NSR studies have different obligations, as explained below.

 

What is a Significant Risk Device Study?

According to 21 CFR 812.3(m), a SR device is an investigational device that:

  • Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;
  • Is purported or represented to be for use supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;
  • Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or
  • Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

As a consequence of an SR designation, the sponsor must submit an IDE application to get agency approval before conducting the planned study. Then, the clinical investigators must follow 21 CFR Parts 50, 56, and 812 as they conduct the study.

 

What is a Nonsignificant Risk Device Study?

An NSR device study is simply one that does not meet the definition for an SR device study. As a consequence of NSR designation, the sponsor does NOT need to submit an IDE application to the FDA. However, the sponsor should provide the IRB an explanation of its determination why the study is NSR (ex: a device description, proposed investigational plan, subject selection criteria, etc.).

 

Differences Between SR and NSR Device Studies

To summarize, SR studies have more rigorous requirements: they must follow all of the IDE regulations in 21 CFR 812, and must have an IDE application approved by the FDA before the study. On the other hand, NSR studies need only follow the abbreviated requirements in 21 CFR 812.2(b) (addressing things like labeling, IRB approval, informed consent, monitoring, records, reports, and prohibition against promotion). NSR studies do not require an approved IDE application, and do not have to make progress reports or final reports to the FDA. The rationale is that the IRB will serve as the “FDA’s surrogate for review, approval, and continuing review of the NSR device studies.”

Check the FDA guidance linked above for examples of SR and NSR devices. Read more of our FDA posts here: FDA Tag

About the author

Amy enjoys researching and writing about developments in medical technology and how that intersects with US law. She received her J.D. from the University of Florida Levin College of Law in 2020 and now works as a Regulatory Associate for SoftwareCPR®, a general-purpose regulatory consulting firm that is recognized globally for their expertise with standards and national regulations pertaining to medical device, mobile medical app, and HealthIT software.

SoftwareCPR Training Courses:

IEC 62304 and other emerging standards for Medical Device and HealthIT Software

Our flagship course for preparing regulatory, quality, engineering, operations, and others for the activities and documentation expected for IEC 62304 conformance and for FDA expectations. The goal is to educate on the intent and purpose so that the participants are able to make informed decisions in the future.  Focus is not simply what the standard says, but what is meant and discuss examples and approaches one might implement to comply.  Special deep discount pricing available to FDA attendees and other regulators.

3-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Brian Pate

Next public offering:  June 5-7, 2024
Boston, MA

Email training@softwarecpr.com to request a special pre-registration discount.  Limited number of pre-registration coupons.

Registration Link:

Register Now

 


 

Being Agile & Yet Compliant (Public or Private)

Our SoftwareCPR unique approach to incorporating agile and lean engineering to your medical device software process training course is now open for scheduling!

  • Agile principles that align well with medical
  • Backlog management
  • Agile risk management
  • Incremental and iterative software development lifecycle management
  •  Frequent release management
  • And more!

2-days onsite (4 days virtual) with group exercises, quizzes, examples, Q&A.

Instructors: Mike Russell, Ron Baerg

Next public offering: February 12-15, 2024

Virtual via Zoom

Registration Link:

Register Now

 


 

Medical Device Cybersecurity (Public or Private)

This course takes a deep dive into the US FDA expectations for cybersecurity activities in the product development process with central focus on the cybersecurity risk analysis process. Overall approach will be tied to relevant standards and FDA guidance documentation. The course will follow the ISO 14971:2019 framework for overall structure but utilize IEC 62304, IEC 81001-5-1, and AAMI TIR57 for specific details regarding cybersecurity planning, risk characterization, threat modeling, and control strategies.

2-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Dr Peter Rech, 2nd instructor (optional)

Next public offering:  TBD

Corporate Office

15148 Springview St.
Tampa, FL 33624
USA
+1-781-721-2921
Partners located in the US (CA, FL, MA, MN, TX) and Canada.